Skip to main navigation
  • Our Science
  • AT-527
  • COVID-19
  • About Atea
    • About Us
    • Pipelines & Programs
    • Leadership
  • Investors
    • Overview
    • News & Events
      • News Releases
      • Events & Presentations
      • Publications
    • Financials
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
    • Stock Info
      • Stock Quote & Chart
      • Historical Price Look up
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Shareholder Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
      • RSS Feeds
  • Careers
  • Contact
The tip of a pipette pointing towards droplets suspended in a green solution.

Investor Relations

Publications

Breadcrumb

  1. Investors
  2. News & Events
  3. Publications

Publications

Preclinical Evaluation of AT-527, a Novel Guanosine Nucleotide Prodrug with Potent, Pan-genotypic Activity Against Hepatitis C Virus
Source
Published in PLoS ONE. 2020. DOI: e0227104.
Read More
Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis
Source
Published in Antimicrobial Agents & Chemotherapy. 2019. Volume 63, Issue 12. DOI: 10.1128/AAC.01201-19.
Read More

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
Investor FAQs
RSS Feeds
Email Alerts
Contact IR

Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment.

  • Atea Pharmaceuticals, Inc.
  • 225 Franklin Street
  • Suite 2100
  • Boston, MA 02110
  • (857) 284-8891

Copyright © 2023 By Atea Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy | Terms of Use